Financial Contrast: Connect Biopharma (NASDAQ:CNTB) and Veracyte (NASDAQ:VCYT)

Connect Biopharma (NASDAQ:CNTB) and Veracyte (NASDAQ:VCYT) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Profitability

This table compares Connect Biopharma and Veracyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-165.41%	-121.58%
Veracyte	20.37%	9.26%	8.61%

Valuation & Earnings

This table compares Connect Biopharma and Veracyte”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$2.95 million	21.15	-$55.48 million	($1.19)	-0.83
Veracyte	$561.90 million	6.59	$66.35 million	$1.41	32.68

Veracyte has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Connect Biopharma and Veracyte, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1	0	7	0	2.75
Veracyte	1	2	6	2	2.82

Connect Biopharma presently has a consensus price target of $6.86, suggesting a potential upside of 591.24%. Veracyte has a consensus price target of $55.78, suggesting a potential upside of 21.05%. Given Connect Biopharma’s higher possible upside, research analysts plainly believe Connect Biopharma is more favorable than Veracyte.

Insider & Institutional Ownership

58.7% of Connect Biopharma shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 1.6% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Connect Biopharma has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500. Comparatively, Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500.

Summary

Veracyte beats Connect Biopharma on 10 of the 15 factors compared between the two stocks.

About Connect Biopharma

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

About Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.